Prebiotics and Mental Health: Behavioural
- Conditions
- Emotion RegulationAnxiety
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: GOS
- Registration Number
- NCT04616937
- Lead Sponsor
- University of Surrey
- Brief Summary
A behavioural study of the microbiota-gut-brain axis in brain development and mental health
- Detailed Description
Research suggests that modifying microbial ecology therapeutically via the intake of so-called 'psychobiotics' could help reduce stress responses and symptoms of anxiety and depression (Burnet \& Cowen, 2013; Dinan, Stanton, \& Cryan, 2013; Tang, Reddy, \& Saier, 2014). The term psychobiotics refers to both, beneficial gut bacteria (probiotics), as well as prebiotics, which enhance the growth of beneficial gut bacteria (Sarkar et al., 2016). In a recent study, Schmidt and colleagues explored the effects of prebiotics on the secretion of the stress hormone cortisol and emotional processing in healthy volunteers (Schmidt et al., 2015). They found that cortical awakening response was significantly lower after BimunoÒ-galacto-oligosaccharides (Bimuno) intake over 4 weeks compared with placebo. Moreover, participants exhibited decreased attentional vigilance to negative information in a dot-probe task. Given that anxious people show increased biases towards negative information (Bar-Haim, Lamy, Pergamin, Bakermans-Kranenburg, \& van, 2007), this suggests that prebiotic intake may be useful in modifying anxiety-related cognitive mechanisms.
These findings will be extended to a sample of late adolescents in order to investigate how prebiotic intake for 4 weeks affects cognitive functioning, psychological well-being and gut microbiota a sample of 60 undergraduate students (aged 18-25 years).
At time 1 (pre-assessment), participants in both groups will undergo comprehensive behavioural and psychological testing to establish baseline measures of cognitive functioning and psychological well-being (such as anxiety levels) and asked to collect a stool sample at home for 16s rRNA sequencing of the microbiome. Group 1 will then receive a daily dosage of a galactooligosaccharide (GOS) prebiotic over 4 weeks, whereas group 2 will receive a placebo over the same period. At time 2 (post-assessment), both groups will again undergo cognitive and psychological testing and stool sampling.
Hypothesis: It is predicted that the treatment group (GOS) will show improvements in behavioural indices of emotion regulation (e.g. dot probe task) and in self reported psychological measures related to emotion regulation (e.g. anxiety) in comparison to the placebo group. Changes/differences in gut microbiome samples will be explored.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 64
- Females
- Aged between 18-25
- Clinical levels of anxiety and/ or co-morbid diagnoses (e.g. depression)
- Current or previous neurological disorders
- Current or previous psychiatric disorders
- Current or previous gastrointestinal disorders
- Current or previous endocrine disorders
- Antibiotic use 3 months prior to the study
- Regular use of pre- and probiotics, including 3 months prior to the study
- Vegan diets
- BMI >30
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo group Placebo Daily dose of maltodextrin over 4 weeks Galacto-oligosaccharides (GOS) Group GOS Daily dose of GOS over 4 weeks
- Primary Outcome Measures
Name Time Method Changes in self reported indices of anxiety. 4 weeks Changes in self reported anxiety as measured by the Trait Anxiety subscale of the State-Trait Anxiety Inventory (Spielberger, 1978) in the prebiotic group compared to placebo group. For this inventory, a lower overall score is the desired outcome.
Changes in self reported indices of anxiety 3. 4 weeks Changes in self reported social anxiety measured by Social Anxiety Scales (La G reca 1999) in the prebiotic group compared to placebo group. For this scale, a lower overall score is the desired outcome.
Changes in self reported emotion regulation (Thought control ability). 4 weeks Changes in the prebiotic group compared to placebo for Thought control ability (Luciano et al 2005). For this questionnaire, a higher overall score is the desired outcome.
Changes in self reported indices of anxiety 2. 4 weeks Changes in self reported anxiety as measured by the State Anxiety subscale of the State-Trait Anxiety Inventory (Spielberger, 1978) in the prebiotic group compared to placebo group. For this inventory, a lower overall score is the desired outcome.
Changes in self reported emotion regulation (Emotion regulation strategies). 4 weeks Changes in the prebiotic group compared to placebo for emotion regulation strategies (Gross \& John, 2003). For this questionnaire, a higher overall score is the desired outcome.
Changes in self reported mood 4 weeks Changes in the prebiotic group compared to placebo for mood and feelings as measured by the mood and feelings questionnaire (Angold etal., 1995). A lower overall score is the desired outcome.
Behavioural indices of emotion regulation 4 weeks Changes in performance on dot-probe task measured as attentional bias to emotional stimuli in milliseconds in the prebiotic group compared to placebo. Increased attentional bias to positive stimuli and/or decreased attentional bias to negative stimuli is the desired outcome.
Changes in self reported depression. 4 weeks Changes in the prebiotic group compared to placebo for depression as measured by the Depression inventory (Beck \& Steer, 1984). A lower score is the desired outcome.
- Secondary Outcome Measures
Name Time Method Gut microbiota changes 4 weeks Changes in gut microbiome composition in diversity, or in abundance of genera (%) (e.g. Bifidobacterium) from pre to post assessment in prebiotic group compared to placebo OR between prebiotic and placebo groups at post assessment.
Trial Locations
- Locations (1)
University of Surrey
🇬🇧Guildford, Surrey, United Kingdom